PMID- 19178670
OWN - NLM
STAT- MEDLINE
DCOM- 20090310
LR  - 20131121
IS  - 1476-5829 (Electronic)
IS  - 1476-5810 (Linking)
VI  - 6
IP  - 2
DP  - 2008 Jun
TI  - Dose-escalating vinblastine for the treatment of canine mast cell tumour.
PG  - 111-9
LID - 10.1111/j.1476-5829.2007.00147.x [doi]
AB  - The purpose of this study was to evaluate the short-term adverse events (AEs) in 
      dogs with mast cell tumours (MCT) receiving prednisone and dose-escalating 
      vinblastine (VBL). Twenty-four dogs were treated with intravenous VBL starting at 
      2 mg m(-2) and then escalating in weekly increments to 2.33, 2.67 and 3 mg m(-2). 
      AEs were graded using a standardized scoring system. No dogs receiving 2 or 2.33 
      mg m(-2) experienced grade 3 or 4 AEs. Among the dogs, 9.5 and 5.9% had grade 3 
      or 4 AEs at dosages of 2.67 and 3 mg m(-2), respectively. Serious AEs included 
      neutropaenia (n = 3) and vomiting (n = 1), only one of which required 
      hospitalization. These data indicate that VBL chemotherapy may be safe to 
      administer at higher than the traditional 2 mg m(-2) dosage for dogs with MCT. 
      Randomized prospective trials are necessary to establish whether dose escalation 
      will translate into improved response rates when compared with the standard 2 mg 
      m(-2) dosage.
FAU - Vickery, K R
AU  - Vickery KR
AD  - The Animal Cancer Center, Colorado State University, Fort Collins, CO 80523-1620, 
      USA.
FAU - Wilson, H
AU  - Wilson H
FAU - Vail, D M
AU  - Vail DM
FAU - Thamm, D H
AU  - Thamm DH
LA  - eng
PT  - Journal Article
PL  - England
TA  - Vet Comp Oncol
JT  - Veterinary and comparative oncology
JID - 101185242
RN  - 0 (Antineoplastic Agents)
RN  - 5V9KLZ54CY (Vinblastine)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/*therapeutic use
MH  - Dog Diseases/*drug therapy/mortality
MH  - Dogs
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Male
MH  - Mast-Cell Sarcoma/drug therapy/mortality/*veterinary
MH  - Neoplasm Metastasis
MH  - Treatment Outcome
MH  - Vinblastine/*administration & dosage/*therapeutic use
EDAT- 2009/01/31 09:00
MHDA- 2009/03/11 09:00
CRDT- 2009/01/31 09:00
PHST- 2009/01/31 09:00 [entrez]
PHST- 2009/01/31 09:00 [pubmed]
PHST- 2009/03/11 09:00 [medline]
AID - VCO147 [pii]
AID - 10.1111/j.1476-5829.2007.00147.x [doi]
PST - ppublish
SO  - Vet Comp Oncol. 2008 Jun;6(2):111-9. doi: 10.1111/j.1476-5829.2007.00147.x.